AI Engines For more Details: Perplexity Kagi Labs You
Antioxidant Activity: Taxifolin exhibits strong antioxidant properties, scavenging free radicals and reactive oxygen species (ROS) that can damage cells and contribute to oxidative stress. By neutralizing oxidative stress, taxifolin may help protect cells and tissues from oxidative damage, reduce inflammation, and prevent the development of chronic diseases such as cardiovascular disease, neurodegenerative disorders, and cancer.
Cardiovascular Health: Taxifolin may have cardioprotective effects and help promote cardiovascular health. It has been shown to improve endothelial function, enhance nitric oxide (NO) production, and reduce oxidative stress and inflammation in the cardiovascular system. Taxifolin may help lower blood pressure, improve blood vessel function, and reduce the risk of atherosclerosis, myocardial infarction, and stroke.
Liver Health: Taxifolin has hepatoprotective properties and may support liver health and function. It can protect liver cells from damage caused by toxins, drugs, and oxidative stressors. Taxifolin may help reduce liver inflammation, fibrosis, and lipid accumulation, thereby preventing or alleviating liver disorders such as non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, and drug-induced liver injury.
Neuroprotection: Taxifolin may have neuroprotective effects and help preserve cognitive function and brain health. It can cross the blood-brain barrier and exert antioxidant, anti-inflammatory, and anti-apoptotic actions in the brain. Taxifolin may protect neurons from oxidative damage, reduce neuroinflammation, and enhance neuronal survival and synaptic plasticity. It may have potential therapeutic applications in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and stroke.
Anti-inflammatory Effects: Taxifolin possesses anti-inflammatory properties and may help modulate inflammatory pathways and reduce inflammation throughout the body. It can inhibit the production of pro-inflammatory cytokines and mediators, such as tumor necrosis factor-alpha (TNF-Ξ±) and interleukin-6 (IL-6). Taxifolin's anti-inflammatory effects may be beneficial for conditions associated with chronic inflammation, such as arthritis, inflammatory bowel disease (IBD), and asthma.
Anticancer Potential: Taxifolin has been investigated for its potential anticancer properties and ability to inhibit tumor growth and metastasis. It can induce apoptosis (programmed cell death) in cancer cells, inhibit cell proliferation, and suppress angiogenesis (formation of new blood vessels) and tumor invasion. Taxifolin may have chemopreventive effects against various types of cancer, including breast, prostate, colon, and lung cancer.
Skin Health: Taxifolin may have protective effects on skin health and help prevent skin aging and damage caused by UV radiation and environmental stressors. It can neutralize free radicals, reduce oxidative stress, and inhibit matrix metalloproteinases (MMPs) that degrade collagen and elastin fibers in the skin. Taxifolin may help maintain skin elasticity, hydration, and barrier function, leading to a more youthful and radiant complexion.
Rank | Probiotic | Impact |
---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.3 | 0.6 | -1 |
Allergic Rhinitis (Hay Fever) | 0.5 | 0.5 | |
Allergies | 0.4 | 0.4 | |
Allergy to milk products | 0.5 | 0.5 | |
Alopecia (Hair Loss) | 0.2 | 0.2 | |
Alzheimer's disease | 1 | 1.3 | -0.3 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.2 | 0.2 | |
Ankylosing spondylitis | 0.4 | 1.3 | -2.25 |
Anorexia Nervosa | 0.5 | -0.5 | |
Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
Asthma | 0.3 | 0.7 | -1.33 |
Atrial fibrillation | 0.5 | 1.1 | -1.2 |
Autism | 0.5 | 1.7 | -2.4 |
Bipolar Disorder | 0.8 | 0.3 | 1.67 |
Brain Trauma | 1.1 | -1.1 | |
Carcinoma | 0.5 | 0.5 | 0 |
Celiac Disease | 0.8 | 0.8 | 0 |
Cerebral Palsy | 0.5 | -0.5 | |
Chronic Fatigue Syndrome | 1.1 | 0.5 | 1.2 |
Chronic Kidney Disease | 0.5 | 0.5 | |
Chronic Lyme | 0.5 | -0.5 | |
Chronic Urticaria (Hives) | 0.2 | -0.2 | |
Colorectal Cancer | 0.9 | 0.3 | 2 |
Constipation | 0.9 | 0.9 | |
COVID-19 | 2.6 | 2.9 | -0.12 |
Crohn's Disease | 1.7 | 1.3 | 0.31 |
cystic fibrosis | 0.5 | -0.5 | |
Depression | 1.9 | 2 | -0.05 |
Eczema | 0.3 | 0.2 | 0.5 |
Endometriosis | 0.5 | 0.5 | |
Epilepsy | 0.7 | 0.5 | 0.4 |
Fibromyalgia | 0.5 | 0.7 | -0.4 |
Functional constipation / chronic idiopathic constipation | 1.3 | 0.8 | 0.63 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.3 | |
Generalized anxiety disorder | 0.5 | -0.5 | |
giant cell arteritis | 0.6 | 0.6 | |
Gout | 0.3 | 0.3 | |
Graves' disease | 0.5 | 0.5 | |
Halitosis | 0.5 | 0.5 | |
Hashimoto's thyroiditis | 0.5 | 0.5 | 0 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.5 | 0.5 | |
hyperglycemia | 0.5 | -0.5 | |
hypertension (High Blood Pressure | 0.5 | 1.3 | -1.6 |
Hypoxia | 0.5 | 0.5 | |
IgA nephropathy (IgAN) | 0.7 | -0.7 | |
Inflammatory Bowel Disease | 1.8 | 0.7 | 1.57 |
Insomnia | 0.5 | 0.8 | -0.6 |
Intelligence | 0.2 | 0.2 | |
Intracranial aneurysms | 0.5 | 0.5 | |
Irritable Bowel Syndrome | 1.1 | 1.7 | -0.55 |
Liver Cirrhosis | 0.5 | 1.1 | -1.2 |
Long COVID | 3.1 | 1.2 | 1.58 |
Lung Cancer | 0.2 | 0.2 | |
ME/CFS with IBS | 0.5 | -0.5 | |
ME/CFS without IBS | 0.5 | -0.5 | |
Menopause | 0.2 | 0.2 | |
Metabolic Syndrome | 1.5 | 1.4 | 0.07 |
Mood Disorders | 1.9 | 2 | -0.05 |
Multiple Sclerosis | 0.3 | 1.7 | -4.67 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.5 | -0.5 | |
NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
Obesity | 1.6 | 1.4 | 0.14 |
obsessive-compulsive disorder | 1 | 0.5 | 1 |
Osteoarthritis | 1 | 1 | |
Osteoporosis | 0.5 | 0.5 | 0 |
Parkinson's Disease | 0.8 | -0.8 | |
Polycystic ovary syndrome | 0.5 | 0.5 | |
primary biliary cholangitis | 0.2 | -0.2 | |
Psoriasis | 0.2 | 0.5 | -1.5 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.8 | 1.8 | -1.25 |
Schizophrenia | 0.7 | 0.6 | 0.17 |
Sjögren syndrome | 0.7 | -0.7 | |
Sleep Apnea | 0.5 | -0.5 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | -0.6 | |
Stress / posttraumatic stress disorder | 0.5 | 0.7 | -0.4 |
Systemic Lupus Erythematosus | 1.8 | 1.8 | |
Tourette syndrome | 0.5 | -0.5 | |
Type 1 Diabetes | 0.8 | 0.8 | |
Type 2 Diabetes | 1.2 | 1.6 | -0.33 |
Ulcerative colitis | 1.1 | 1.1 | 0 |
Unhealthy Ageing | 0.7 | 0.6 | 0.17 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.